Actinic keratosis and capecitabine therapy

Higa, Gerald M.; Kovach, Rodney; Abraham, Jame

doi:10.1191/1078155205jp163cr

Cited by 11 publications

(19 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Seventy percent of patients reported grade 3 and 4 adverse events; most commonly, fatigue, gout, palmar–plantar erythrodysesthesia, gastrointestinal distress, and reduced kidney function (Table ) . The data presented in this case study as well as those found in previous case reports support the use of capecitabine for the chemoprevention of SCC in solid organ transplant recipients on prolonged immunosuppressive therapy …”

Section: Capecitabinesupporting

confidence: 77%

“…Previous studies examining the effect of capecitabine on these tumors subsequently discovered that patients who have concurrent actinic keratosis seemed to have some treatment benefit and lesion resolution . Previous case reports on three solid organ transplant recipients and non‐transplant recipients with large NMSC tumor burden showed that low‐dose capecitabine resulted in fewer NMSCs with relatively mild adverse effects . The author of that report published an additional case study on 10 solid organ transplant recipients.…”

Section: Capecitabinementioning

confidence: 99%

See 1 more Smart Citation

Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies

2015

View full text Add to dashboard Cite

Nonmelanoma skin cancer (NMSC) is the most common cancer in patients and includes basal cell carcinoma (BCC) and squamous cell carcinoma (SCC). Treatments useful for SCC and BCC include surgical, topical, and in advanced cases systemic chemo-radiation. This review of the literature aims to describe previous and current treatment options for oral therapy in locally advanced and metastatic NMSC otherwise unamenable to standard treatment. Oral Smoothened (Smo) inhibitors Vismodegib, Sonidegib, and Taladegib have shown to be effective in several trials. Oral tyrosine kinase inhibitors Erlotinib and Gefitinib, which target epidermal growth factor receptor (EGFR), have early supporting data and are currently undergoing large multicenter trials. Other less studied oral therapies which have shown at least partial efficacy include 5-Fluorouracil, capecitabine, and picropodophyllin. In vitro studies have elucidated new targets for dual combination oral therapy targeting both EGFR and insulin-like growth factor 1 receptor (IGF-1R). It is important to stratify treatment options based on patient risk of advanced disease, failure of conservative treatment, and ill-tolerated intravenous chemotherapy adverse events. Oral therapy in NMSC is useful in high risk patients with recurrent and aggressive disease who may not tolerate other systemic therapies.

show abstract

Section: Capecitabinesupporting

confidence: 77%

Section: Capecitabinementioning

confidence: 99%

Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies

2015

View full text Add to dashboard Cite

show abstract

“…Other conventional chemotherapeutic agents which have been associated with the inflammation of actinic keratosis include docetaxel, doxorubicin, capecitabine, pentostatin, sorafenib and the combination of dactinomycin, vincristine, dacarbazine and doxorubicin, cytarabine and 6-thioguanine (8,12,23,24). The mechanism by which these agents lead to this effect is unknown, although abnormal DNA synthesis and a form of radiation recall have been postulated (12).…”

Section: Actinic Keratoses and Squamous Cell Carcinomasmentioning

confidence: 99%

Erlotinib-responsive actinic keratoses

Hermanns

Pierard²,

Quatresooz³

2007

Oncol Rep

View full text Add to dashboard Cite

Abstract.Erlotinib is an inhibitor of the tyrosine-kinase domain of the epidermal growth factor receptor-1 (EGFR). This drug is used to treat some solid cancers, particularly advanced non-small-cell lung carcinoma. Similar to other EGFR inhibitors, erlotinib is responsible for a series of skin adverse reactions, particularly acneiform lesions. We described the incidental effect of erlotinib on actinic keratoses which became markedly inflamed and showed partial regression. Inflammation appeared to spontaneously decrease while on erlotinib treatment. This reaction in the skin neoplasm is perhaps a visible and accessible model for predicting the effect in the deep-seated neoplasm targeted by the drug.

show abstract

“…The data presented in the previous case reports support the use of capecitabine for the chemoprevention of SCC in solid organ transplant recipients on prolonged immunosuppressive therapy [75,76,77]. …”

Section: Classical Therapy Of Nmscsmentioning

confidence: 97%

Neoplastic Multifocal Skin Lesions: Biology, Etiology, and Targeted Therapies for Nonmelanoma Skin Cancers

Fernandes

Santos²,

Kovačević³

et al. 2017

Skin Pharmacol Physiol

View full text Add to dashboard Cite

Neoplastic skin lesions are multifocal, diffuse skin infiltrations of particular relevance in the differential diagnosis of ulcerative, nodular, or crusting skin lesions. Nonmelanoma skin cancers (NMSCs), namely, basal cell carcinoma (BCC), squamous cell carcinoma (SCC), and also actinic keratosis (AK), are the most common malignant tumors in humans. BCCs do not proliferate rapidly and most of the times do not metastasize, while SCCs are more infiltrative, metastatic, and destructive. AKs are precursor lesions of cutaneous SCCs. The classical therapy of NMSCs makes use of photodynamic therapy associated with chemotherapeutics. With improved understanding of the pathological mechanisms of tumor initiation, progression, and differentiation, a case is made towards the use of targeted chemotherapy with the intent to reduce the cytotoxicity of classical treatments. The present review aims to describe the current state of the art on the knowledge of NMSC, including its risks factors, oncogenes, and skin carcinogenesis, discussing the classical therapy against new therapeutic options.

show abstract

Actinic keratosis and capecitabine therapy

Cited by 11 publications

References 6 publications

Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies

Oral therapy for nonmelanoma skin cancer in patients with advanced disease and large tumor burden: a review of the literature with focus on a new generation of targeted therapies

Erlotinib-responsive actinic keratoses

Neoplastic Multifocal Skin Lesions: Biology, Etiology, and Targeted Therapies for Nonmelanoma Skin Cancers

Contact Info

Product

Resources

About